A systematic approach to improving antimicrobial use, with a view to improving clinical outcomes and minimising adverse events relating to their use
In addition to the six monthly reports below, National Utilisation Surveillance Program (NAUSP) also produces detailed annual reports showing usage of an expanded number of antimicrobials both nationally and in individual Australian public and private hospitals in a de-identified manner.
Prior to January 2021, total-hospital acute usage rates included usage in the emergency department and operating theatres. Usage in these areas will now be reported separately relative to patient presentations (replacing occupied bed days as a measure of patient activity), and are not included in total-hospital (or non-Critical Care) from January 2021.
Some usage rates continued to fluctuate during the January to June 2021 reporting period. OBDs dropped markedly for some hospitals in some months, with consequential increases in reported usage rates. Usage rates should be interpreted with caution as they reflect the quantity of antimicrobials distributed or dispensed from pharmacy and not actual consumption at patient level. Some hospitals were unable to submit complete data for the reporting period due to the impact of COVID-19 on staffing capacity.
January 2020 to December 2021
These 2-year longitudinal reports include aggregated usage by all contributors for both total hospital use and Critical Care (including Intensive Care and High Dependency Units) use.
July 2021 to December 2021
These six-monthly reports allow contributors to compare their usage with other hospitals within their state or territory.
July 2021 to December 2021
For hospitals able to submit Emergency Department (ED) usage data, these reports allow contributors to benchmark their ED usage rates with other hospitals in their state/territory.
For hospitals able to submit usage data for their Critical Care Unit, these reports allow contributors to benchmark their Critical Care usage rates (Intensive Care and/or High Dependency Units) with other hospitals in their AIHW peer group.
These six-monthly reports allow contributors to compare their antifungal usage rates with other hospitals within their state or territory. Usage rates of antifungals are highly dependent on the casemix (e.g. haematology/oncology or transplant services) and acuity of the hospital.
New South Wales and Australian Capital Territory (PDF 634KB)
Queensland and Northern Territory (PDF 638KB)
South Australia (PDF 644KB)
Victoria (PDF 165KB)
Western Australia (PDF 649KB)
Tasmania (PDF 883)
Hospitals contributing to NAUSP can download reports directly from the NAUSP portal showing longitudinal usage rates for their individual hospitals. These contain charts comparing the individual hospital’s usage compared to the average usage at similarly peered hospitals. Hospitals that contribute usage data for particular specialties/locations can access usage reports for critical care, haematology/oncology, respiratory and obstetrics/gynaecology.
Usage rates reported in previously published NAUSP reports may differ from current reports. The Defined Daily Dose (DDD) values for some commonly used antimicrobials were changed by the WHO in January 2019. Due to these changes, usage rates in more recently published reports may not be directly comparable with prior reports that utilised the former DDD values for the analysis. In addition to amendments to WHO DDDs, rates may differ as a result of retrospective data adjustments or varying numbers of hospitals contributing to aggregated data.
The Australian Department of Health provides funding for the administration of NAUSP and the analyses of NAUSP data and related reports for the AURA Surveillance System.
Unless otherwise stated within a report, please attribute the reports found on this webpage (and any material sourced from them) using the following citation:
National Antimicrobial Utilisation Surveillance Program. [insert report title]. Adelaide: SA Health; [insert year of publication].
For further information on National Antimicrobial Utilisation Surveillance Program, contact the Program Coordinator.